MUC5AC/β-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors

Figure 4 Histology and immunohistochemistry of laterally spreading tumors. Immunoreactive scores (IRSs) for Gr-LGD: MUC2, 4 points; MUC5AC, 2 points; MUC6, 0 points; CD10, 0 points; p53, 0 points; nuclear β-catenin, 0 points. IRSs for NGr-LGD: MUC2, 3 points; MUC5AC, 1 points; MUC6, 0 points, CD10, 0 points; p53, 0 points; nuclear β-catenin, 1 points. IRSs for Gr-HGD: MUC2, 1 points; MUC5AC, 1 points; MUC6, 0 points, CD10, 1 points; p53, 1 points; nuclear β-catenin, 1 points. IRSs for NGr-HGD: MUC2, 2 points; MUC5AC, 1 points; MUC6, 1 points, CD10, 1 points; p53, 1 points; nuclear β-catenin, 2 points. IRSs for Gr-INV: MUC2, 1 points; MUC5AC, 1 points; MUC6, 0 points, CD10, 1 points; p53, 4 points; nuclear β-catenin, 1 points. IRSs for NGr-INV: MUC2, 1 points; MUC5AC, 0 points; MUC6, 2 points, CD10, 2 points; p53, 2 points; nuclear β-catenin, 2 points (H and E, ×80; immunoperoxidase: MUC2, MUC5AC and MUC6, ×100; CD10 and p53, ×120; β-catenin, ×300); LGD: Adenoma with low grade dysplasia; HGD: Adenoma with high grade dysplasia; INV: Adenocarcinoma invading into submucosa; Gr: Granular; NGr: Non-granular.